axicabtagene ciloleucel
gilead,daiichi sankyo
['zuma7', 'axi-cel']
dr. ghobadi: subsequent therapy in zuma7 axi-cel (2nd line). 3rd line chemo common. 3rd line cellular therapy (soc arm) worse than 2nd line. 3rd line car t after 2nd line axi-cel can be an option #ash22 
Hem/Onc, BMT, CAR-T, Immunology, Math, Machine Learning, Python, R, SAS. Tweets are my personal views